Long-Term Cardiomyopathy Risk Varies by Chemo Agent

FRIDAY, March 1, 2019 -- Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology. Elizabeth A.M....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news